Safety experience with caspofungin in pediatric patients

We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events...

Full description

Saved in:
Bibliographic Details
Published inThe Pediatric infectious disease journal Vol. 28; no. 12; p. 1132
Main Authors Zaoutis, Theoklis, Lehrnbecher, Thomas, Groll, Andreas H, Steinbach, William J, Jafri, Hasan S, Maertens, Johan, Ngai, Angela L, Chow, Joseph W, Taylor, Arlene F, Strohmaier, Kim M, Bourque, Michael, Bradshaw, Susan K, Petrecz, Maria, Kartsonis, Nicholas A
Format Journal Article
LanguageEnglish
Published United States 01.12.2009
Subjects
Adolescent
Antifungal Agents - adverse effects
Antifungal Agents - therapeutic use
Child
Child, Preschool
Clinical Trials as Topic
Echinocandins - adverse effects
Echinocandins - therapeutic use
Humans
Infant
Infant, Newborn
Lipopeptides
Mycoses - drug therapy
Prospective Studies
Online AccessGet more information

Cover

More Information
Summary:We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.
ISSN:1532-0987
DOI:10.1097/INF.0b013e3181af5a15